Tonix Pharmaceuticals Logo

  • About
    • Leadership
      • Executive Team
      • Board of Directors
    • Facilities
  • Therapeutic Areas Overview
    • Central Nervous System
      • Fibromyalgia
      • Posttraumatic Stress Disorder
      • Long Covid
      • Cocaine Intoxication
      • Migraine
      • Depression
    • Immunology
      • Organ Transplant Rejection
      • Gastro-Intestinal Cancers
    • Infectious Disease
      • COVID-19
      • Monkeypox
      • Smallpox
    • Rare Disease
      • Prader-Willi Syndrome
  • Pipeline
    • Central Nervous System
      • TNX-102 SL
      • TNX-601 ER
      • TNX-1300
      • TNX-1900
    • Immunology
      • TNX-1500
      • TNX-1700
    • Infectious Disease
      • TNX-1850
      • TNX-801
      • TNX-3600
    • Rare Disease
      • TNX-2900
    • Scientific Presentations
    • Expanded Access Policy
  • Clinical Trials
  • News & Events
    • Tonix in the News
    • Press Releases
    • Investor Presentations
    • IR Events
    • Op-eds
  • Investors
    • News & Events
    • Presentations
    • Multimedia
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact Us

Tonix is enrolling in a Phase 3 study for Fibromyalgia, and Phase 2 studies for Long COVID, Chronic Migraine, and Major Depressive Disorder. Please visit Clinical Trials.

Multimedia

Investors

Investors

  • Overview
  • News & Events
    • Tonix in the News
    • Press Releases
    • IR Events
    • Email Alerts
    • Op-Eds
  • Presentations
  • Multimedia
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
New York City based pharmaceutical company chooses College Station to manufacture possible coronavirus vaccine
Jun 1, 2020

New York City based pharmaceutical company chooses College Station to manufacture possible coronavirus vaccine

Tonix Pharmaceuticals Discusses Developing COVID-19 Vaccine in Collaboration with Southern Research
May 28, 2020

Tonix Pharmaceuticals Discusses Developing COVID-19 Vaccine in Collaboration with Southern Research

MicroCap Investing Workshop: Potential Solutions for Addressing the Coronavirus Pandemic
Apr 21, 2020

MicroCap Investing Workshop: Potential Solutions for Addressing the Coronavirus Pandemic

Tonix Pharmaceuticals (NASDAQ: TNXP) | CEO Seth Lederman | 'Innovators with Jane King'
Feb 3, 2020

Tonix Pharmaceuticals (NASDAQ: TNXP) | CEO Seth Lederman | 'Innovators with Jane King'

rss_feed RSS
  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
email icon Sign up for Email Alerts
twitter icon linkedin icon facebook icon
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • Site Map

© 2023 Tonix Pharmaceuticals Holding Corp.